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Direct oral anticoagulants (DOACs) specifically target factor IIa or Xa and represent a major step forward in the treatment of acute- and long-
term prevention of venous thrombo-embolism (VTE). They are at least as effective and as safe as conventional therapy (heparins and vitamin-K
inhibitors) and have practical advantages, such as fixed dosing and no need for laboratory monitoring. These antithrombotic agents introduce a
new paradigm for the day-to-day management of VTE. Direct oral anticoagulants should streamline the management of most patients with VTE
and will facilitate care in the outpatient setting. Nevertheless, it remains uncertain how to select specific DOACs for particular profiles of patients,
and the optimal management of bleeding complications is evolving.
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Introduction
During the past six decades, treatment of venous thrombo-embolism
(VTE) utilized anticoagulants characterized by an indirect mode of
action (such as heparins) or anticoagulants targeting several coagula-
tion factors [vitamin-K antagonists (VKA)]. Direct oral anticoagulants
(DOACs) differ in many respects, including fixed dosing, rapid onset
of action, fewer food and drug interactions, and no need for labora-
tory coagulation monitoring.1
Direct oral anticoagulants can be categorized as either direct
thrombin (FIIa) inhibitors (such as dabigatran) or direct factor Xa
(FXa) inhibitors (such as rivaroxaban, apixaban, or edoxaban). Direct
FIIa inhibitors bind to thrombin in the early phase of its generation and
blunt theconsecutiveactivationof factorsV,VIII, andXI that are involved
in the burst of thrombin production. They also inhibit the main function
of thrombin, conversion of soluble fibrinogen into insoluble fibrin.
DirectFXa inhibitorstarget theactivesiteofFXaandthus inhibit thepro-
thrombinase complex that leads to the formation of thrombin (Figure 1).
Direct oral anticoagulants share common pharmacological prop-
erties summarized in Table 1. In addition to their oral formulation,
the onset of action is similar across all molecules, ranging from 2 to
4 h with an average half-life of 10 h.1,2 The relatively short half-life
of DOACs is consequently associated with a large intraday variabil-
ity in the pharmacokinetic profile. For example, a pharmacokine-
tic model based on Phase II studies of rivaroxaban showed that the
plasma concentration of the drug after administering 20 mg may
range from .400 ng/mL at peak to ,30 ng/mL 24 h later.3
Two important features differentiate DOACs. First, renal impair-
ment has a strong impact on the pharmacokinetic and pharmacody-
namic profile of dabigatran, whereas apixaban and edoxaban seem
to be less affected by moderate renal insufficiency (Table 1).2
Second, DOACs have different metabolisms, especially regarding
the implication of cytochrome P450 (CYP)3A4 (Table 1). While
all four DOACs are being eliminated via the P-glycoprotein (P-gp)
transporter after absorption, CYP3A4 activity is involved in the riv-
aroxaban, apixaban, and edoxaban metabolisms but does not affect
significantly the dabigatran pharmacokinetic profile.4 This import-
ant feature is associated with potentially fewer drug–drug interac-
tions with dabigatran.5 However, the majority of the drugs that
affects CYP3A4 function and also affects P-gp, since CYP3A4 and
P-gp share many substrates and inhibitors and have a common
tissue distribution.6 Although many of these drugs also interact
with VKA, the risk of concomitant treatment is mitigated by the
availability of INR.7
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Acute and long-term treatment
of venous thrombo-embolism
Conventional anticoagulant treatment of acute deep vein thrombosis
(DVT) and pulmonaryembolism (PE) consistsof an initial course of at
least 5 days of parenteral (usually s.c.) administration of unfractio-
nated or low-molecular-weight heparin (LMWH) or fondaparinux
(acute phase), overlapped and followed by VKA such as warfarin
for at least 3 months, a period known as the long-term treatment
phase.8,9 This conventional treatment has been compared with
various regimens of DOACs (Figure 2, and Tables 2–5).
Of note, Phase III trials addressing the efficacy and safety of rivar-
oxaban, dabigatran, and apixaban in acute and long-term treatment
of VTE had a single-dose regimen for patients allocated to the
study treatment. Among all four pivotal trials with DOACs for
stroke prophylaxis in atrial fibrillation, a reduced dose option was
available in patients with renal insufficiency, as it is the casewith edox-
aban in the VTE programme.
Dabigatran
Dabigatran etexilate (150 mg b.i.d.) has been compared with
conventional anticoagulant treatment in the RE-COVER10 and
RE-COVER II studies. Patients could be included if they had symp-
tomatic DVT and/or PE. Of note, in both studies, randomization
was preceded by a mandatory phase of at least 5 days of LMWH.
The two trials were randomized, double-blinded, and aimed at
establishing non-inferiority. RE-COVER included 2564 patients and
the still unpublished RE-COVER II (NCT 00680186) included 2589
patients. In RE-COVER, symptomatic VTE or death occurred in
2.4% of dabigatran-treated patients, compared with 2.1% receiving
conventional therapy. The rate of major bleeding was similar in the
two groups (1.6 and 1.9%, respectively). Of note, the treatment dis-
continuation rate was significantly higher in the dabigatran arm (9%)
than in the control arm (6.8%), mainly due to dyspepsia attributed to
dabigatran in 3% of patients. In RE-COVER II, non-inferiority was
established for dabigatran with respect to efficacy [2.4% recurrent
VTE, compared with 2.2% with conventional therapy, and major
Figure 1 Coagulation process and targets of direct oral anticoagulants (DOACs). Contrarily to DOACs, vitamin-K antagonists (VKA) have multiple
targets (including factors II, VII, IX and X).
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Table 1 Pharmacological characteristics of direct oral anticoagulants
Dabigatran Rivaroxaban Apixaban Edoxaban
Target FIIa FXa FXa FXa
Onset of action 2 h 2.5–4 h 3 h 1–5 h
Half-life 12–14 h 9–13 h 8–11 h 8–10 h
Renal clearance (%) 80 60 25 35
Metabolism P-gp P-gp/CYP3A4 P-gp/CYP3A4 P-gp/CYP3A4
Dosing b.i.d. b.i.d./qd b.i.d. b.i.d./qd
FIIa, factor IIa; FXa, factor Xa; P-gp, P-glycoprotein; CYP, cytochrome P450.
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Table 2 Selected characteristics of the studies with the DOACs in venous thrombo-embolism
Treatment/drug Study Dosage (mg) Comparator Indication Design Initial LMWH
Initial/dabigatran RE-COVER 150 b.i.d. Conventional DVT or PE DB Mandatory
Initial/dabigatran RE-COVER II 150 b.i.d. Conventional DVT or PE DB Mandatory
Initial/rivaroxaban EINSTEIN-DVT 15 b.i.d./20 o.d. Conventional DVT Open Optional, ,48 h
Initial/rivaroxaban EINSTEIN-PE 15 b.i.d./20 o.d. Conventional PE Open Optional ,48 h
Initial/apixaban AMPLIFY 10 b.i.d./5 b.i.d. Conventional DVT or PE DB Optional ,36 h
Initial/edoxaban HOKUSAI-VTE 60 o.d. Conventional DVT or PE DB Mandatory
Extended/dabigatran RE-SONATE 150 b.i.d. Placebo DVT or PE DB NA
Extended/dabigatran RE-MEDY 150 b.i.d. Warfarin DVT or PE DB NA
Extended/rivaroxaban EINSTEIN-EXT 20 o.d. Placebo DVT or PE DB NA
Extended/apixaban AMPLIFY-EXT 5 b.i.d. OR 2.5 b.i.d. Placebo DVT or PE DB NA
O.d. and b.i.d., once or twice daily, respectively; DB, double-blind, NA, not applicable.
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Table 3 Summary of the main results with the DOACs in venous thrombo-embolism: main efficacy endpoint
Treatment/drug Study Comparator VTE recurrence (%)
active/control
HR/RR (95% CI)
Initial/dabigatran RE-COVER Conventional 2.4/2.1 1.10 (0.60–1.84)
Initial/dabigatran RE-COVER IIa Conventional 2.4/2.2 1.09 (0.65–1.81)
Initial/rivaroxaban EINSTEIN-DVT Conventional 2.1/3.0 0.68 (0.44–1.04)
Initial/rivaroxaban EINSTEIN-PE Conventional 2.1/1.8 1.12 (0.75–1.68)
Initial/apixaban AMPLIFY Conventional 2.3/2.7 0.84 (0.60–1.18)
Initial/edoxaban HOKUSAI-VTE Conventional 3.2/3.5 0.89 (0.70–1.13)
Extended/dabigatran RE-SONATE Placebo 0.4/5.6 0.08 (0.02–0.25)
Extended/dabigatran RE-MEDY Warfarin 1.8/1.3 1.44 (0.78–2.64)
Extended/rivaroxaban EINSTEIN-EXT Placebo 1.3/7.1 0.18 (0.09–0.39)
Extended/apixaban AMPLIFY-EXT Placebo 2.5 mg b.i.d.: 1.7/8.8 2.5 mg: 0.33 (0.22–0.48)
5 mg b.i.d.: 1.7/8.8 5 mg: 0.36 (0.25–0.53)
NA, not applicable; HR and RR, hazard ratio and relative risk, respectively.
aFull data yet unpublished.
Figure 2 Summary of the main Phase III trials regarding acute and extended treatment of venous thrombo-embolism. Low-molecular-weight
heparin has to be given upfront for the initiation of the treatment with dabigatran and edoxaban (A) while a single-drug approach drives the treatment
with rivaroxaban and apixaban both in the initiation and the early maintenance phases (B).
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bleeding (1.2 vs. 1.7%, respectively)]. Overall, the RE-COVER trials
demonstrated non-inferiority of efficacy compared with convention-
al therapy, with similar safety.
Rivaroxaban
Rivaroxaban (15 mg b.i.d. during the first 3 weeks, then 20 mg o.d.)
has been compared with conventional anticoagulant treatment in
the EINSTEIN-DVT11 and EINSTEIN-PE12 studies. In the former,
patients were included if they had symptomatic DVT with or
without asymptomatic PE and in the latter, patients had to have symp-
tomatic PE with or without DVT. The two trials were randomized,
open, and aimed at establishing non-inferiority of the two regimens.
Their results have been pooled in a pre-specified analysis on 8281
patients that allowed for studying clinically important high-risk
subgroups, including frail patients, patients with cancer, moderate
renal insufficiency, recurrent VTE events, or a large clot burden. Al-
though these patients had an increased risk of thrombo-embolic re-
currence and of major bleeding, the efficacy and safety of rivaroxaban
was at least as good as conventional therapy.13 Of note, rivaroxaban
could be given upfront without initial administration of LMWH in
both studies that encompassed 3449 patients (EINSTEIN-DVT)
and 4832 patients (EINSTEIN-PE). In EINSTEIN-DVT, symptomatic
VTE or VTE-related death occurred in 2.1% of rivaroxaban-treated
patients, compared with 3.0% in the controls. The corresponding
figures were 2.1 and 1.8% in EINSTEIN-PE. In EINSTEIN-DVT, the
principal safety outcome (major bleeding plus clinically relevant non-
major bleeding) was observed in 8.1% in both arms. In EINSTEIN-PE,
the corresponding figures were 10.3% (rivaroxaban-treated
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Table 4 Summary of the main results with the DOACs in venous thrombo-embolism: bleeding endpoints
Study Major bleeding (%)
active/control
HR/RR (95% CI) Major or clinically relevant
non-major bleeding event (%)
HR/RR (95% CI)
RE-COVER 1.6/1.9 0.82 (0.45–1.48) 5.1/8.8 0.63 (0.47–0.84)
RE-COVER IIa 1.2/1.7 0.69 (0.66–1.33) NA 0.42 (0.45–0.84)
EINSTEIN-DVTb 0.8/1.2 0.65 (0.33–1.30) 8.1/8.1 0.97 (0.76–1.22)
EINSTEIN-PEb 1.1/2.2 0.49 (0.31–0.79) 10.3/11.4 0.90 (0.76–1.07)
AMPLIFY 0.6/1.8 0.31 (0.17–0.55) 4.3/9.7 0.44 (0.36–0.55)
HOKUSAI-VTEb 1.4/1.6 0.84 (0.59–1.21) 8.5/10.3 0.81 (0.71–0.94)
RE-SONATE 0.3/0 NA 5.3/1.8 2.92 (1.52–5.6)
RE-MEDY 0.9/1.8 0.52 (0.27–1.02) 5.6/10.2 0.54 (0.41–0.71)
EINSTEIN-EXT 0.7/0 NA 6.0/1.2 5.19 (2.3–11.7)
AMPLIFY-EXT 2.5: 0.2/0.5 2.5:0.49 (0.09–2.64) 2.5:3.2/2.7 2.5:1.20 (0.69–2.10)
5: 0.1/0.5 5: 0.25 (0.03–2.24) 5:4.3/2.7 5:1.62 (0.96–2.73)
Bleeding was defined as major if it was clinically overt and associated with a decrease in the haemoglobin level of 2.0 g/dL or more, if bleeding led to the transfusion of two or more units
of red cells, or if bleeding occurred in a critical site, or contributed to death.
aFull data yet unpublished. NA, not applicable; HR and RR, hazard ratio and relative risk, respectively.
bIn EINSTEIN-DVT, EINSTEIN-PE, and HOKUSAI-VTE, the principal safety outcome was not major bleeding but major bleeding plus clinically relevant non-major bleeding.
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Table 5 Numbers of patients with deep vein thrombosis only or pulmonary embolism (with or without deep vein
thrombosis) in the various trials with direct oral anticoagulants in venous thrombo-embolism
Treatment/drug Study Patients (n) With DVT (n) With PE (n)
Initial/dabigatran RE-COVER 2534 1749 785
Initial/dabigatran RE-COVER II 2589 a a
Initial/rivaroxaban EINSTEIN-DVT 3428 3405 23
Initial/rivaroxaban EINSTEIN-PE 4832 0 4832
Initial/apixaban AMPLIFY 5368 3532 1836
Initial/edoxaban HOKUSAI-VTE 8240 4921 3319
Extended/dabigatran RE-SONATE 1315 872 443
Extended/dabigatran RE-MEDYb 2854 1860 994
Extended/rivaroxaban EINSTEIN-EXT 1196 742 454
Extended/apixaban AMPLIFY-EXT 2482 1622 860
aDetails unpublished yet.
bComparator in this study was warfarin, in all other studies on extended treatment, comparator arm was placebo.
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patients) and 11.4% (controls). The rates of major or clinically rele-
vant nonmajor bleeds are displayed in Table 4. Surprisingly, in the
pooled analysis, the reduction in major bleeding in favour of rivarox-
abanwasmostpronounced inpatients aged75yearsormore(1.2 and
4.5% in rivaroxaban-treated patients and control, respectively, P,
0.05) as well as in those with moderate renal impairment with a cre-
atinine clearance ,50 mL/min (0.9 and 4.1% in rivaroxaban-treated
patients and control, respectively, P, 0.05).13
Overall, the EINSTEIN-DVT and EINSTEIN-PE studies demon-
strated non-inferiority in terms of efficacy, compared with conven-
tional therapy, with similar safety.
Apixaban
Apixaban (10 mg b.i.d. during the first 7 days, followed by 5 mg b.i.d.)
was compared with conventional anticoagulant treatment in
AMPLIFY.14 Patients were included if they had symptomatic DVT
and/or PE, and apixaban could be given upfront without initial admin-
istration of LMWH. The study was randomized, double-blinded, and
aimed at establishing non-inferiority of apixaban. The study included
5395 patients. During the treatment period, symptomatic VTE recur-
rence or VTE-related death occurred in 2.3% of apixaban-treated
patients and in 2.7% of patients treated with the conventional
regimen, resulting in non-inferiority of the apixaban regimen. Major
bleeding was less frequent among the apixaban-treated patients
(0.6%), compared with 1.8% in the conventional therapy group
(P, 0.001). Likewise, the combined outcome of major and
clinically relevant non-major bleeding was less frequent in the
apixaban arm (4.3%) than in the conventional treatment arm (9.7%,
P, 0.001).
Overall, AMPLIFY demonstrated that apixaban is non-inferior to
conventional anticoagulant therapy with significantly less bleeding.
Edoxaban
Edoxaban (60 mg o.d.) has been compared with conventional anti-
coagulant treatment for VTE in the HOKUSAI-VTE study,15 the
largest study ever for VTE treatment. Patients were included if they
had symptomatic DVT and/or PE. The study was randomized,
double-blinded, and aimed at establishing non-inferiority of the two
regimens. A minimal initial 5-day period with parenteral administra-
tion of LMWH was mandatory in the two arms. HOKUSAI-VTE en-
rolled 8292 patients. Recurrent VTE during the study period
occurred in 130 of 4118 patients (3.2%) in the edoxaban group and
in 146 of 4122 patients (3.5%) in the warfarin group, resulting in non-
inferiority of the edoxaban regimen. Among the pre-specified sub-
group of patients with PE and evidence of right ventricular dysfunc-
tion (NT-pro-BNP level of ≥500 pg/mL), recurrent VTE occurred
in 15 of 454 patients (3.3%) in the edoxaban group and in 30 of 484
patients (6.2%) in the warfarin group (hazard ratio: 0.52; 95% confi-
dence interval: 0.28–0.98). Similar results were observed among
patients with right ventricular dysfunction as assessed by means of
computed tomography.15 Major bleeding did not differ between
groups (1.4% among the edoxaban-treated patients and 1.6% in the
warfarin-treated group, P ¼ 0.35). However, the primary safety
outcome of major plus clinically relevant non-major bleeding was
less frequent in the edoxaban arm (8.5%), compared with 10.3% in
the conventional therapy group (P ¼ 0.004).
Extended treatment of venous
thrombo-embolism
Following the first 3 months of anticoagulant treatment, it is often dif-
ficult to determine whether treatment should be continued. Clinical
equipoise surrounding this decision led to ‘extension’ studies in
which the DOACs were compared with placebo (except in one
case with warfarin). These extension studies were randomized,
double-blinded, and aimed at establishing superiority (non-inferiority
in the RE-MEDY study that used warfarin as comparator) of the
DOAC, after an initial phase of at least 3 months of treatment with
an approved anticoagulant regimen (Tables 2–4).
Dabigatran
RE-MEDY (n ¼ 2856) assessed dabigatran (150 mg b.i.d.) vs. war-
farin, and RE-SONATE (n ¼ 1343) assessed dabigatran vs. placebo
in separate extension studies published together in the same manu-
script.16 The patients included must have received an initial phase
of at least 3 (RE-MEDY) or 6 (RE-SONATE) months of anticoagula-
tion. In the dabigatran and warfarin arms of RE-MEDY, the principal
efficacy outcome occurred in 1.8 and 1.3% of patients, respectively
(P ¼ 0.01 for non-inferiority). The corresponding figures in
RE-SONATE were 0.4 and 5.6% in the dabigatran-treated patients
and placebo controls, respectively (P, 0.001 for superiority).
Major bleeding occurred in 0.9% (dabigatran-treated patients) and
1.8% (warfarin controls, P ¼ 0.06) in RE-MEDY, and 0.3%
(dabigatran-treated patients) and 0% (placebo controls) in
RE-SONATE. If major plus clinically relevant non-major bleeding
was assessed, this outcome was recorded in 5.2% of dabigatran-
treated patients, compared with 10.6% of warfarin-treated patients
in RE-MEDY (P, 0.001). In RE-SONATE, the corresponding
figures were 5.3% (dabigatran-treated patients) and 1.8% (placebo
controls, P, 0.001). In RE-MEDY, 0.9% of dabigatran-treated
patients experienced an acute coronary syndrome compared with
0.2% in warfarin-treated patients (P, 0.02).
Overall, dabigatran was effective and safe in the extended treat-
ment of VTE.
Rivaroxaban
The EINSTEIN-Extension study (n ¼ 1197) is a randomized and
double-blind superiority study that was published together with
the EINSTEIN-DVT study.11 Patients were eligible for the extension
study if they had completed an initial course of at least 6 months of
anticoagulation and if the treating physician had clinical equipoise as
to whether anticoagulation should be continued. They received
either rivaroxaban (20 mg o.d.) or placebo for 6–12 months. Recur-
rent symptomatic VTE occurred in 1.3% of rivaroxaban-treated
patients, compared with 7.1% of placebo patients (P, 0.0001), an
82% relative and a 5.8% absolute risk reduction. Major bleeds were
observed 0.7% of rivaroxaban-treated patients and in none of the
patients receiving placebo (P ¼ 0.106). Clinically, relevant non-major
bleeding was more frequent with rivaroxaban (5.4%) than placebo
(1.2%).
Overall, rivaroxaban was effective in the extended treatment of
VTE but had a higher bleeding risk than placebo.
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Apixaban
The AMPLIFY-Extension study17 included 2486 patients who had
completed an initial course of at least 6 months of anticoagulation.
The study was randomized, double-blinded, and placebo-controlled.
Two active groups were compared with placebo: apixaban 2.5 and
5 mg b.i.d. for 12 months. During the treatment period, recurrent
symptomatic VTE occurred in 1.7% (2.5 mg b.i.d.), 1.7% (5 mg
b.i.d.), and 8.8% (placebo), resulting in a relative risk of recurrence
of 0.33 (2.5 mg b.i.d.) and 0.36 (5 mg b.i.d.) against placebo. The cor-
responding rates of major bleeding were 0.2% (2.5 mg b.i.d.), 0.1%
(5 mg b.i.d.), and 0.5% (placebo). In addition, no difference was
found in non-major clinically relevant bleeding between placebo
and the lower dosage of apixaban.
Overall, apixaban was effective in the extended treatment of VTE,
with the lower 2.5 mg b.i.d. dose showing an advantage over the 5 mg
b.i.d. dose with respect to safety.
Lessons from the development
programme of the direct oral
anticoagulants in venous
thrombo-embolism
A meta-analysis has summarized the data from randomized con-
trolled trials of DOACs compared with VKA for the acute treatment
of VTE, with data on .16 000 patients,18 but not including
HOKUSAI-VTE. There were no significant differences in efficacy
when comparing DOACS vs. conventional therapy. Rivaroxaban
and apixaban reduced the risk of major bleeding compared with con-
ventional treatment, whereas dabigatran did not.
Data on the extended treatment of VTE showed that DOACs
were associated with a favourable safety profile, even when com-
pared with placebo,11,17 except for dabigatran at 150 mg twice
daily.16 The two apixaban regimens tested (2.5 and 5 mg b.i.d.)
were as safe as placebo for major bleeding, and the lower dosage
was as safe as placebo for non-major clinically relevant bleeding. Of
note, the term ‘clinically relevant bleeding’ usually includes major
bleeding that was defined the same way across studies, adhering to
the recommendations of the International Society on Thrombosis
and Haemostasis, and thus allowing comparison of trials (Table 4).
The non-major component is less strictly defined, and therefore a
comparison across studies becomes more problematic.
Vitamin-K antagonists or direct oral
anticoagulants for my next venous
thrombo-embolism patient?
Besides these main data that favour DOACs, some practical differ-
ences maybe considered when selecting a DOAC in day-to-day prac-
tice. Those include the need for an upfront administration of LMWH
(dabigatran and edoxaban regimens, Figure 2), twice daily dosing
(dabigatran and apixaban regimens), and a change in the dosing of
the drug during the treatment (rivaroxaban and apixaban) that may
influence adherence by patients and acceptance by clinicians. The
absence of drug monitoring may also influence adherence to treat-
ment and practitioners may be reluctant to prescribe a critical treat-
ment without any regular and objective information on compliance.
Although a fixed dose regimen would favour these drugs in third
world countries, the cost associated with DOACs is a major limita-
tion. Cost-effectiveness studies are indeed lacking regarding VTE
treatment for most of these DOACs but pioneered evaluation of riv-
aroxaban based on data of the EINSTEIN trials and on the US health-
care system studies suggest that rivaroxaban would be cost-effective
most of the time.19 Cost-effectiveness issues will certainly influence
the decision regarding the choice of anticoagulant treatment. Large
registries suggest that the risk/benefit ratio of anticoagulation may
vary over time;20 this may also influence drug selection or dosage
for long-term prophylaxis. The relative weight of an often reversible
haemorrhagic event compared with the recurrence of a venous
thrombotic event that may be associated with long-term conse-
quences should also be taken into account. Finally, a VKA-treated
patient with excellent INR control has probably little to gain by
switching to DOACs since the net clinical benefit may not favour




Although the pro-thrombin time is relatively more sensitive to oral
FXa inhibitors and the activated partial thromboplastin time to dabi-
gatran, the usual coagulation tests routinely available do not precisely
reflect the anticoagulation effect of DOACs,22 especially in the low
range of values. Moreover, these results are highly dependent on
the reagents used and may thus differ from one laboratory to
another.23 The subcommittee on control of anticoagulation of the
scientific and standardization committee of the International
Society on Thrombosis and Haemostasis recommends that the
dilute thrombin time in combination with dabigatran calibrants
should be used to determine dabigatran level (Hemoclot assay24),
while anti-Xa assays with rivaroxaban calibrants can be used to deter-
mine rivaroxaban plasma levels.25 It is likely that determination of
other direct oral FXa inhibitor such as apixaban or edoxaban
should be possible with an anti-Xa assay using dedicated calibrants.
The interpretation of the results will remain challenging and will be
more qualitative than quantitative until ‘therapeutic ranges’ are
determined.26
Bleeding and bleeding management
When major bleeding occurs with DOACs, optimal management
remains uncertain. American College of Chest Physician guidelines
recommend reversal of warfarin by using 4-factor pro-thrombin
complex concentrates (PCC) in conjunction with vitamin K.27
However, the reversal of bleeding from DOACs is not addressed.
Most studies conducted of DOAC reversal agents were performed
in healthy volunteers using laboratory coagulation endpoints or clin-
ical endpoints in animal models. Moreover, the available data are
mostly related to rivaroxaban and dabigatran, with fewdata regarding
apixaban and edoxaban. Thus, recommendations regarding bleeding
management result more from experts’ opinions rather than clinical
experience. For example, the European Heart Rhythm Association28
a multidisciplinary French29 and American group30 provide guidance
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that may help the practitioner in managing bleeding events in patients
treated with DOACs.
Overall, since DOACs have a short half-life, time is an efficient way
to eliminate the anticoagulant effect. When a life-threatening bleed-
ing occurs, non-specific agents such as PCC (25–50 U/kg) or acti-
vated PCC (30–50 U/kg) should be considered as a first-line
treatment. Reserve recombinant activated factor VII as a second-line
treatment. Adjunctive therapy such as desmopressin or tranexamic
acidmayalso beconsidered, although the data regarding their efficacy
in DOAC-associated bleeding are even more scarce. Specific anti-
dotes are in development31,32 and may dramatically change the
bleeding management of these patients in the next future.
Perioperative management
Surgery is a well-known risk factor for VTE. The management of in-
vasive procedures in patients with previous DVTand/or PE is particu-
larly challenging since it may require modification or temporary
discontinuation of the anticoagulant. One should perform for each
patient a careful assessment of the bleeding risk associated with the
continuation of the anticoagulant (procedure specific) and the
thrombotic risk in case of discontinuation (both patient and proced-
ure specific).33
Since renal function is a major determinant of the DOACs elimin-
ation (Table 1), creatinine clearance is a key factor in deciding how
long to wait between DOAC withdrawal and the invasive procedure.
In patients with normal renal function who undergo a low-
haemorrhagic risk procedure such as a colonoscopy without
removal of large polyps, a stop of the DOAC 24 h before surgery is
proposed.7 If renal function is impaired (Cockcroft creatinine clear-
ance ,50 mL/min) and/or the haemorrhagic and thrombotic risks
are moderate to high, withdrawal of the DOAC for 2–5 days may
be warranted, with a bridging procedure in selected cases.34– 37
Conclusion
Direct oral anticoagulants represent a major step forward in the
treatment and long-term prevention of VTE. Fixed dosing, few
food and drug interactions, and no need for laboratory coagulation
monitoring are major advantages compared with VKA. However,
this simplification of treatment, along with a shift towards outpatient
management of VTE, may inappropriately trivialize the importance of
VTE and its treatment. Recurrence of VTE as well as bleeding events
has serious consequences that should not be overlooked. Finally,
some issues remain unanswered, such as the effects of DOACs in
the setting of cancer, their use in patients with mechanical heart
valve, and the availability of a specific reversal agent.
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